This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy

This study has been completed.
Information provided by:
Institute of Cardiology, Warsaw, Poland Identifier:
First received: January 11, 2009
Last updated: February 4, 2013
Last verified: February 2013

Paroxysmal or chronic atrial fibrillation (AF) develops in about 20- 25% of adult patients with hypertrophic cardiomyopathy (HCM) and represents an important complication in the clinical course of the disease, with adverse long-term consequences on functional status and outcome.

Therefore, aggressive therapeutic strategies are indicated to restore and maintain sinus rhythm (SR) in patients with HCM. Nevertheless, pharmacologic prevention of AF recurrence is challenging because of the limited long-term efficacy and potentially hazardous side effects of available treatment options. Currently radiofrequency catheter ablation (RFCA) of AF is successfully used in clinical practice. However, comparison of the efficacy and safety of these two therapeutic options has not been done up till now in randomized manner in this group of patients.

Thus, the aim of the present study is to compare the efficacy and safety of RFCA vs. antiarrhythmic drug therapy in patients with HCM and AF.

Condition Intervention Phase
Atrial Fibrillation Hypertrophic Cardiomyopathy Procedure: RF catheter ablation Drug: Antiarrhythmic drugs Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sinus Rhythm Maintenance in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation - Randomized Comparison of Antiarrhythmic Therapy vs. Radiofrequency Catheter Ablation (SHAARC)

Resource links provided by NLM:

Further study details as provided by Institute of Cardiology, Warsaw, Poland:

Primary Outcome Measures:
  • Efficacy: Freedom from atrial fibrillation and atrial flutter (>1 min) on or off antiarrhythmic medications. [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Changes in total symptomatic and asymptomatic AF burden. [ Time Frame: 1 year ]
  • Incidence of complications. [ Time Frame: 1 year ]
  • Changes in left atrial diameter and left ventricular function. [ Time Frame: 1 year ]
  • Changes in level of Nt-pro-BNP. [ Time Frame: 1 year ]
  • Changes in symptom severity and quality of life. [ Time Frame: 1 year ]
  • Changes in exercise capacity assessed by cardiopulmonary exercise testing. [ Time Frame: 1 year ]

Estimated Enrollment: 90
Study Start Date: January 2009
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: RFCA Procedure: RF catheter ablation
RF catheter ablation
Active Comparator: Drug Drug: Antiarrhythmic drugs
One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with hypertrophic cardiomyopathy and paroxysmal or chronic atrial fibrillation

Exclusion Criteria:

  • Severe hear failure (NYHA IV)
  • Left ventricular ejection fraction <0.30
  • Left atrial diameter >65 mm
  • Age > 70 years
  • Contraindication to anticoagulation with warfarin
  • Presence of a mechanical prosthetic valve
  • Presence of left atrial thrombus on TEE or CT
  • Woman currently pregnant
  • Renal failure (GFR < 30 ml/min)
  • Hepatic failure
  • Untreated hypothyroidism or hyperthyroidism
  • LVOT gradient > 50 mmHg
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00821353

Institute of Cardiology
Warsaw, Poland
Sponsors and Collaborators
Institute of Cardiology, Warsaw, Poland
Principal Investigator: Pawel Derejko, MD, PhD Institute of Cardiology, Warsaw, Poland
Principal Investigator: Lidia Chojnowska, MD, PhD Institute of Cardiology, Warsaw, Poland
Principal Investigator: Lukasz Szumowski, MD, PhD Institute of Cardiology, Warsaw, Poland
Principal Investigator: Franciszek Walczak, MD, PhD Institute of Cardiology, Warsaw, Poland
  More Information

Responsible Party: Pawel Derejko M.D. Ph.D., Institute of Cardiology, Warsaw, Poland Identifier: NCT00821353     History of Changes
Other Study ID Numbers: N N402 194635
Study First Received: January 11, 2009
Last Updated: February 4, 2013

Keywords provided by Institute of Cardiology, Warsaw, Poland:
Atrial fibrillation
Hypertrophic cardiomyopathy
RF ablation
Antiarrhythmic drugs

Additional relevant MeSH terms:
Atrial Fibrillation
Cardiomyopathy, Hypertrophic
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Pathological Conditions, Anatomical
Aortic Stenosis, Subvalvular
Aortic Valve Stenosis
Heart Valve Diseases
Anti-Arrhythmia Agents processed this record on September 21, 2017